Navigation Links
New drug strategies for Alzheimer's, multiple sclerosis examined at UH
Date:10/20/2011

HOUSTON, Oct. 20, 2011 Researchers at the University of Houston (UH) are recommending a new strategy for developing drugs to treat cancer, multiple sclerosis, Alzheimer's and cardiovascular diseases.

In an invited review published in the October issue of Nature Reviews Drug Discovery, scientists at the Center for Nuclear Receptors and Cell Signaling (CNRCS) at UH outline the results of years of research following the team's 1996 discovery of the estrogen receptor beta (ERβ).

"We have known for some time that female sex hormones estrogens influence a number of functions in the human body," said Dr. Jan-ke Gustafsson, UH professor and CNRCS director. "Only recently have we and others found that one of the estrogen receptors ERβ is a potential target for the treatment of Alzheimer's and other chronic diseases."

Gustafsson is best known as a leading expert on estrogen receptors, being credited with the earlier discovery of ERβ during his tenure at the Karolinska Institutet in Stockholm, Sweden. In Houston since 2009, Gustafsson has hand-selected a team of experts to build on his initial breakthrough. For this latest review, the team was invited to share the most recent results of their research.

The two estrogen receptors, estrogen receptor alpha (ERα) and ERβ, have their effects on cells via activation by hormones circulating in the body. The influence of these receptors in the human body spans such diverse functions as fertility, metabolism, and the cardiovascular and nervous systems. Due to their expanded role in human health, these receptors represent an ideal target for drugs and therapeutic treatments.

Studies conducted following Gustafsson's discovery of ERβ have shown intriguing differences in tissue distribution and gene regulation when compared to the role of ERα. There has since been an intense effort in both academia and industry to develop ERβ-specific research tools and potential therapeutics for a multitude of conditions.

One successful example of using ERβ as a drug target has proven the receptor as an effective cancer cell combatant in breast cancer tissue. Closer examination of human breast cancer cell lines determined that, while ERα alone may stimulate the development of tumors, the combined presence of ERα and ERβ reduced and prevented tumor development.

"These modulators are well-established in the treatment of breast cancer and osteoporosis," Gustafsson said. "We now are pushing the limits of their influence to develop new treatments and ultimately save lives."

CNRCS researchers continue to examine the two estrogen receptor subtypes in various animal disease models, focused on identifying therapeutic opportunities. ERβ remains the most likely target for expanding treatments beyond breast cancer. The widespread involvement of ERβ presents the greatest probability for impacting these other diseases. Early results indicate that the selective activation of ERβ may represent a safe, disease-modifying therapy for the treatment of Alzheimer's disease.


'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert  

Related medicine news :

1. Bone experts to present strategies for osteoporosis prevention and care in Dubai
2. New data-based strategies and treatment models can improve diabetes care for older African-Americans
3. UF researchers suggest cholera vaccination strategies for Zimbabwe
4. Novel strategies target health care-associated infections
5. Stupid strategies could be best for the genes
6. Penn study on skin formation suggests strategies to fight skin cancer
7. Elsevier/MC Strategies and AORN launch perioperative nursing skills collection
8. Clinical trials demonstrate effective weight loss strategies for obese and overweight adults
9. Study: Mental illness stigma entrenched in American culture; new strategies needed
10. Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women
11. Integrated Healthcare Strategies Senior Consultant Signs Book Deal with American College of Healthcare Executives
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New drug strategies for Alzheimer's, multiple sclerosis examined at UH
(Date:1/24/2017)... ... January 24, 2017 , ... ... natural supplement for relieving premenstrual syndrome, or PMS . , Most women ... These symptoms can include cramps, constipation, irritability, headaches, fatigue, and other discomfort. ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... “Who Would Have Dreamed: A Novel of ... changed each woman who tried to understand its purpose in her life. “Who Would Have ... woman of powerful faith and a love of writing. , Sharon shares that ...
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual ... Octagon of Spiritual Balances” is the creation of published author, Pastor Bernard J. Weathers, ... Weathers holds a bachelor degree in religious education and a master degree in theology. ...
(Date:1/24/2017)... ... January 23, 2017 , ... CLICKco LLC, a ... drink, announced its CLICK® Coffee Protein Drink is now available for purchase on ... has become popular among health-conscious consumers who love coffee but are looking to ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... on the imposition of the Mexico City Policy, also known as the Global ... today through Executive action, prohibits foreign non-governmental organizations from receiving any U.S. foreign ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... Research and Markets has announced the addition of the ... 2025" report to their offering. ... Global Optogenetics Market is poised to grow ... reach approximately $76.24 million by 2025. Some of the ... labs using optogentic techniques for neurosciences, quick growth ultrafast laser tools ...
(Date:1/24/2017)... , January 24, 2017 For ... (NASDAQ: GENE ), Alder Biopharmaceuticals Inc. (NASDAQ: ... BDSI ), and Egalet Corp. (NASDAQ: EGLT ). ... moderately lower on Monday, January 23 rd , 2017, with ... of health care companies in the S&P 500 also were ...
Breaking Medicine Technology: